Compare Abeona Therapeutics Inc (ABEO) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Amplify Transformational Data Sharing ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Amplify Transformational Data Sharing ETF trades at $62.02. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | BLOK | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $74.10 |
52-Week Low | $4.17 | $47.36 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BLOK trades at $63.47, up 3.07% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces resistance at $64 and support at $62. Recent news highlights the ETF's exposure to AI infrastructure and Bitcoin mining stocks, though analyst sentiment has turned cautious due to increased crypto market correlation.
The outlook remains neutral with technical indicators divided and fundamental data limited. Key risks include reliance on volatile crypto markets and competitive ETF pressures. Analyst consensus suggests holding pending clearer catalysts from AI infrastructure growth or Bitcoin market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
